MicroRNA and Protein Profiling of Brain Metastasis Competent Cell-Derived Exosomes

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Camacho, Laura ^a   Guerrero, Paola ^a   Marchetti, Dario ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALNEXIN; CAVEOLIN 1; CD9 ANTIGEN; CYCLIN D1; FIBRONECTIN; INOSITOL POLYPHOSPHATE 4 PHOSPHATASE; LET 7I; MERLIN; MICRORNA; MICRORNA 130A; MICRORNA 17 92; MICRORNA 19A; MICRORNA 210; MICRORNA 29; MICRORNA 29C; NERVE CELL ADHESION MOLECULE; PHOSPHATASE; TUBERIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CELL ADHESION; CELL COMMUNICATION; CONTROLLED STUDY; EXOSOME; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; RNA ANALYSIS; TUMOR INVASION;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL COMMUNICATION; CELL CYCLE; CELL LINE; CELL PROLIFERATION; EXOSOMES; HUMANS; MICRORNAS; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEOMICS;

EID: 84884171136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073790     Document Type: Article

References (58)

1. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18: 883-891.
2. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, et al. (2012) Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 7: e46874.
3. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, et al. (2009) High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One 4: e5219.
4. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ, (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt 19: 3365-3374.
5. Johnstone RM, Bianchini A, Teng K, (1989) Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions. Blood 74: 1844-1851.
6. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, et al. (2010) Exosomes: Fit to deliver small RNA. Commun Integr Biol 3: 447-450.
7. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, et al. (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
8. Smalheiser NR, (2007) Exosomal transfer of proteins and RNAs at synapses in the nervous system. Biol Direct 2: 35.
9. Taylor DD, Gercel-Taylor C, (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21.
10. Yang C, Robbins PD, (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011: 842849.
11. Pant S, Hilton H, Burczynski ME, (2012) The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 83: 1484-1494.
12. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303-1316.
13. Liu C, Yu S, Zinn K, Wang J, Zhang L, et al. (2006) Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 176: 1375-1385.
14. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, et al. (2008) Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 10: 619-624.
15. Tili E, Michaille JJ, Croce CM, (2013) MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253: 167-184.
16. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH, (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46.
17. Mears R, Craven RA, Hanrahan S, Totty N, Upton C, et al. (2004) Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics 4: 4019-4031.
18. Palazzolo G, Albanese NN, G DIC, Gygax D, Vittorelli ML, et al. (2012) Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res 32: 847-860.
19. Ridgway LD, Wetzel MD, Ngo JA, Erdreich-Epstein A, Marchetti D, (2012) Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res 10: 689-702.
20. Zhang L, Ridgway LD, Wetzel MD, Ngo J, Yin W, et al. (2013) The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 5: 179-182.
21. Marchetti D, Menter D, Jin L, Nakajima M, Nicolson GL, (1993) Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int J Cancer 55: 692-699.
22. Raimondo F, Morosi L, Chinello C, Magni F, Pitto M, (2011) Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics 11: 709-720.
23. Thery C, Zitvogel L, Amigorena S, (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
24. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, et al. (1999) Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 147: 599-610.
25. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, et al. (1998) Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 273: 20121-20127.
26. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, et al. (2011) Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 178: 548-571.
27. Kaplan RN, Rafii S, Lyden D, (2006) Preparing the "soil": the premetastatic niche. Cancer Res 66: 11089-11093.
28. Zhang B, Pan X, Cobb GP, Anderson TA, (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12.
29. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, et al. (2007) A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
30. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J, (2010) Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 5: 1755-1763.
31. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, et al. (2010) hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 116: 2148-2158.
32. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, et al. (2009) MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768.
33. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
34. Hong L, Yang J, Han Y, Lu Q, Cao J, et al. (2012) High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis. Gene 507: 135-138.
35. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, et al. (2005) A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632.
36. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
37. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
38. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103: 9136-9141.
39. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, et al. (2010) microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 107: 8231-8236.
40. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, et al. (2008) MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 105: 5874-5878.
41. Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, et al. (2012) MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 33: 1046-1054.
42. Xu J, Chen Y, Olopade OI, (2010) MYC and Breast Cancer. Genes Cancer 1: 629-640.
43. Ruoslahti E, (1984) Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev 3: 43-51.
44. Bartsch JE, Staren ED, Appert HE, (2003) Adhesion and migration of extracellular matrix-stimulated breast cancer. J Surg Res 110: 287-294.
45. Humphries MJ, Olden K, Yamada KM, (1986) A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233: 467-470.
46. Alao JP, (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
47. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL, (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11: 558-572.
48. Gutmann DH, Sherman L, Seftor L, Haipek C, Hoang Lu K, et al. (1999) Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet 8: 267-275.
49. Krymskaya VP, (2003) Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal 15: 729-739.
50. Bartek J, Lukas J, (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429.
51. Mora A, Komander D, van Aalten DM, Alessi DR, (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15: 161-170.
52. Massague J, Seoane J, Wotton D, (2005) Smad transcription factors. Genes Dev 19: 2783-2810.
53. Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, et al. (2004) Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res 10: 2344-2350.
54. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, et al. (1997) Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 3: 230-237.
55. Rubio N, Espana L, Fernandez Y, Blanco J, Sierra A, (2001) Metastatic behavior of human breast carcinomas overexpressing the Bcl-x(L) gene: a role in dormancy and organospecificity. Lab Invest 81: 725-734.
56. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL, (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 9: 5113-5119.
57. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, et al. (2008) Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15: 80-88.
58. Ristorcelli E, Beraud E, Verrando P, Villard C, Lafitte D, et al. (2008) Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J 22: 3358-3369.